Etanercept leads to a rapid recovery of a Dabrafenib‐/Trametinib‐associated toxic epidermal necrolysis‐like severe skin reaction

Targeted therapy with BRAF‐ and MEK‐Inhibitors (BRAFi, MEKi) provides an excellent therapeutic option for patients with malignant melanomas with a BRAF‐Mutation. Mild cutaneous adverse events have been common under the BRAF‐ and MEK‐Inhibitor therapy, on the contrary, severe cutaneous adverse reacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yordanova, Krista, Pföhler, Claudia, Schweitzer, Luca F., Bourg, Catherine, Adam, Leonie, Vogt, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892424/
https://www.ncbi.nlm.nih.gov/pubmed/36751314
http://dx.doi.org/10.1002/ski2.185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892424/
https://www.ncbi.nlm.nih.gov/pubmed/36751314
http://dx.doi.org/10.1002/ski2.185

Ejemplares similares